Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA eyes ways to increase transparency

This article was originally published in Scrip

Executive Summary

US FDA commissioner Dr Margaret Hamburg has announced the creation of a task force to develop recommendations for enhancing transparency at the agency, with a report due in six months. The move has the potential to make more information available to doctors, researchers and the public about agency decision-making, but critics contend that secrecy laws could prove to be an impediment.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC002457

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel